Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MERCURY 3
2015-001528-41Phase 3Unknown
- Sponsor
- Aerie Pharmaceuticals
- Start
- Mar 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in open-angle glaucoma (OAG) and ocular hypertension comparing PG324 Ophthalmic Solution with GANFORT Ophthalmic Solution (2 arms). Primary endpoints: Primary efficacy outcome and Primary safety outcome. Status: unknown.
02
Drugs
netarsudil + latanoprostbimatoprost + timolol
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on 2015-001528-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001528-41.